Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience

Enzalutamide and abiraterone have been shown to improve progression-free survival (PFS) and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients. Moreover, some patients may not benefit from the inhibition of androgen receptor (AR) activity or, alternatively, may...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancers (Basel)
Auteurs principaux: Sepe, Pierangela, Verzoni, Elena, Miodini, Patrizia, Claps, Melanie, Ratta, Raffaele, Martinetti, Antonia, Mennitto, Roberta, Sottotetti, Elisa, Procopio, Giuseppe, Cappelletti, Vera, Daidone, Maria Grazia
Format: Artigo
Langue:Inglês
Publié: MDPI 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6678845/
https://ncbi.nlm.nih.gov/pubmed/31337040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11070980
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires